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Background: VEGF may play a role in the pathogenesis of cancer disease, for example in cell growth, proliferation
and angiogenesis. In this study, we investigated plasma levels of this cytokine in comparison to plasma levels of a
new biomarker - HE4 and the established tumor marker CA125 in ovarian cancer patients (100) as compared to
control groups: patients with a benign ovarian tumor (80) and healthy subjects (50).
Methods: Plasma levels of VEGF were determined by ELISA, HE4 and CA125 by CMIA method.
Results: The results showed that levels of VEGF, CA125 and HE4 were significantly higher in ovarian cancer (OC)
patients as compared to the both control groups. VEGF has demonstrated as high as comparative markers values of
the diagnostic sensitivity (SE), specificity (SP), the predictive values of positive and negative test results (PV-PR, PV-
NR), and the area under the ROC curve (AUC) in early stages of cancer tested groups. The combined use of
parameters studied resulted in the increase in the diagnostic criteria values and the AUC.
Conclusions: These findings suggest the usefulness of VEGF in the early diagnostics of ovarian cancer, especially in
combination with CA125 and HE4, as a new biomarkers panel. Additionally, VEGF is the most useful tool in the
diagnostics of locally advanced ovarian cancer without metastases. Investigated cytokine presented similar to HE4
usefulness in differentiation of OC according to its histopathlogical sub-type, and could be used especially in the
diagnostics of endometrioid epithelial OC.
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Ovarian cancer (OC) is a highly lethal gynecological can-
cer. Approximately 23% of gynecologic cancers are ovar-
ian in origin, but 47% of all deaths from cancer of the
female genital tract occur in women with cancer of this
organ. Malignant tumor of the ovaries occur at all ages
with variation in histological sub-type by age [1,2].
Established risk factors for epithelial ovarian tumors in-
clude reproductive risk factors and inherited patho-
logical mutations in the BRCA1 and BRCA2 genes
[1,3,4]. OC lacks clear syndromes in the beginning,
which prevents early discovery and treatment. Many po-
tential biomarkers have been identified or used during* Correspondence: zdb@umwb.edu.pl
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reproduction in any medium, provided the orlast procedure for diagnostics of ovarian cancer patients
[5,6]. Different types of proteins other than commonly
accepted and used tumor marker - CA125 (carbohydrate
antigen 125) [7-9] or a new biomarker - HE4 (human
epididymis protein 4) [9,10] such as cytokines (M-CSF,
IL-6) [11-14], and metalloproteinases are currently in-
vestigated [15-17].
Angiogenesis has been established as an important factor
in human carcinogenesis influencing tumor growth and in-
vasion [18]. Vascular endothelial growth factor (VEGF)
which can be seen as the most important pro-angiogenic
molecule, has been shown to parallel selective steps of
tumor growth and the development of metastases [19,20]
also through a direct, autocrine effect on tumor cells [21].
Breast and gynecologic cancer are among the best known
malignancies that use lymphangiogenesis, the recruitment of
blood and lymphatic vessels, to a growing tumor [22]. It wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of ovarian cancer patients and
control groups: benign ovarian tumor and healthy
subjects
Study group Number of patients
Epithelial ovarian cancer patients 100 (100%)
• median age (range) 59 (46–87)
- sub-type serous epithelial 54 (54%)
• median age (range) 59 (46–81)
- sub-type endometrioid epithelial 46 (46%)
• median age (range) 59 (49–87)











- postmenopausal 100 (100%)
Benign ovarian tumor patients 80 (100%)
- type cystis serous 40 (50%)
- type cystis endometriosis 40 (50%)
Median age (range) 54 (48–68)
Menopausal status:
- postmenopausal 80 (100%)
Healthy subjects 50 (100%)
Median age (range) 55 (47–64)
Menopausal status:
- postmenopausal 50 (100%)
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role in the development of breast [23], reproductive organ
[24-26] and ovarian cancer [27,28] as well as lung [29], colon
[30], and gastric [31] cancer.
The aim of this study was to determine the plasma
levels of vascular endothelial growth factor in compari-
son with the plasma levels of HE4 and CA125 in epithe-
lial ovarian cancer patients in relation to the control
groups: patients with a benign ovarian tumor and
healthy subjects. Additionally, a comparison between
plasma levels of the parameters tested with the stage of
cancer, its histological sub-type and histological type of
benign ovarian tumors were performed. Moreover, the
diagnostic criteria (sensitivity, specificity, predictive
values of positive and negative test results) and the
receiver-operating characteristic curve (ROC) for the
cytokine tested, HE4 and CA125 alone and in combina-
tions were defined. Furthermore, a correlation between
the parameters tested was established.
These data may be used in the evaluation of the use-
fulness of the VEGF in the diagnosis of stages and histo-
logical sub-types of ovarian cancer and in discrimination
it from benign ovarian tumors, especially when analyzing
with HE4 and CA125.
Methods
Patients
Table 1 shows the tested groups. The study included 100
epithelial ovarian cancer patients (sub-types serous and
endometrioid) diagnosed by the Gynecology Group. Clin-
ical stages and histological classification based on the cri-
teria of the International Federation of Gynecology and
Obstetrics (FIGO) and the World Health Organization
(WHO) were established in all cases. The ovarian cancer
histopathology was established in all cases by tissue biopsy
of tumor or after surgery treatment from tumor cancer
tissues. Patients with renal failure were excluded in our
study because of very high HE4 concentrations levels, un-
distinguishable from ovarian cancer. None of the patients
had received chemo- or radiotherapy before blood sample
collection.
Pretreatment staging procedures included physical and
blood examinations, ultrasound scanning and chest X-
rays. In addition, radioisotope bone scans, the examin-
ation of bone marrow aspirates, and brain and CT scans
were performed where necessary.
The control groups were comprised of 80 benign ovar-
ian tumor patients (cystis serous or cystis endometrioides)
and 50 healthy volunteers. The benign ovarian tumor
histopathology was established in all cases by tissue bi-
opsy of ovary tumor or after surgery.
The healthy women group was examined also by a
gynecologist prior to blood collection and subjects with a
clinical history of prior endometriosis or mild gynecologicalconditions were excluded. In addition, reproductive organ
ultrasound scans or mammary ultrasound scanning were
performed where necessary.
The ovarian cancer patients and the control group (be-
nign lesions) were treated in the Department of
Gynecology, University Hospital in Białystok, Poland, be-
tween 2006–2012 years. The study was approved by the
local Ethics Committee of the Medical University in Bia-
łystok, numbers: R-I-002/314/2009 and R-I-002/262/
2010 and all the patients gave their informed consent for
the participation in the study.
Biochemical analyses
Venous blood samples were collected from every patient.
Blood was collected into a heparin sodium tube, centrifuged
1000 rpm for 15 min. to obtain plasma samples, and stored
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sured with the enzyme-linked immunosorbent assay
(ELISA) (Quantikine Human HGFs Immunoassay, R&D
systems), according to the manufacturer's protocols. Dupli-
cate samples were assessed for each patient.
The intra-assay coefficient of variation (CV%) of VEGF is
reported to be 4.5% at a mean concentration of 235 pg/ml,
SD= 10.6. The inter-assay coefficient of variation (CV%) of
VEGF to be 7.0% at a mean concentration of 250 pg/ml,
SD= 17.4. The assay showed no significant cross-reactivity
or interference with numerous human cytokines and other
growth factors.
The plasma concentrations of CA125 and HE4 were mea-
sured by chemiluminescent microparticle immunoassay
(CMIA) (Abbott, Chicago, IL, USA). The intra-assay CV for
CA125 is reported to be 2.4% at a mean concentration of
43.5 U/ml, SD = 1.1. The inter-assay CV for CA125 - to be
3.9% at a mean concentration of 43.5 U/ml, SD= 1.7. The
intra-assay CV for HE4 - to be 3.7% at a mean concentration
of 39.0 pmol/L, SD= 1.4. The inter-assay CV for HE4 - to
be 2.8% at a mean concentration of 39.0 pmol/L, SD= 1.1.
Statistical analysis
The statistical analysis was performed using the
STATISTICA 8.0 PL program. A preliminary statistical ana-
lysis (Chi-square test) revealed that the distribution of cyto-
kine and tumor marker levels did not follow normal
distribution. Consequently nonparametric methods were
used to compare levels of tumor markers between the
groups of patients. Comparisons between two groups were
performed using the Mann–Whitney test. In case of mul-
tiple groups Kruskal-Wallis tests were calculated with post
hoc comparisons according to Dwass-Steele-Critchlow-
Fligner method. ROC analyses were utilized in the evalu-
ation of diagnostic power of tumor markers. Markers were
compared by assessing the significance of differences be-
tween the areas under their corresponding ROC curves. In
addition, markers were compared by assessing the differ-
ences in sensitivity and specificity obtained for the optimal
cut-off points. These points were determined using the cri-
terion of maximizing the Youden coefficient. The construc-
tion of the ROC curves was performed using GraphRoc
Program for Windows.
Data were presented as median and range. Statistically sig-
nificant differences were defined as comparisons resulting in
p < 0.05. The Spearman rank correlation was used in the
correlation analyses.
The cut-off of VEGF (187.45 pg/ml), HE4 (75.75 pmol/L)
and CA125 (28.89 U/ml) were calculated as 95th percentile
from the control group of healthy blood donors.
Results
In the total group of ovarian cancer (OC) patients’
plasma levels of VEGF (168.48 pg/ml) and tumormarkers, HE4 (103.60 pmol/L) or CA125 (133.30 U/ml)
were found to be statistically higher compared to the
healthy subjects (39.31 pg/ml; 44.15 pmol/L; 9.94 U/ml)
(p < 0.001; respectively) (Table 2). Moreover we observed
all the parameters’ concentrations significantly different
comparing every stage of advancement (I-IV) of studied
cancer with the same control group: I - p < 0.001 (VEGF
and CA125), p = 0.0168 (HE4); II - p = 0.0187, p < 0.001,
p = 0.0023; III - p < 0.001 (respectively); IV - p = 0.0281
(VEGF) p < 0.001 (CA125 and HE4). The plasma levels
of mentioned above cytokine and tumor markers were
also significantly different in the advanced stages (III-IV)
than those found in the early stages (I-II): VEGF, CA125
in comparison of stage III with stage I (p = 0.0440;
p < 0.001) and with II (p = 0.0430; p = 0.0028) or HE4,
CA125 in comparison of stage IV with I (p < 0.001;
p = 0.0032) and II (p = 0.0036; p = 0.0079) of tumor ad-
vancement. The concentrations of VEGF were statisti-
cally higher when comparing patients in stage III with
stage IV (p = 0.0184). We have also noticed significantly
higher (p = 0.0432) concentration of HE4 in OC patients
sub-type serous epithelial compared to sub-type
endometrioid epithelial.
Furthermore, we have observed statistical differences
of the results for VEGF, HE4 and CA125 between
groups with serous epithelial (166.18 pg/ml; 126.00
pmol/L and 171.21 U/ml) or endometrioid epithelial
sub-types of OC (184.24 pg/ml; 68.45 pmol/L and
114.00 U/ml) and with healthy control (Table 2).
Patients with ovarian cancer (total group) had statisti-
cally considerably higher levels of researched factors
(VEGF p = 0.0011; HE4 p < 0.001; CA125 p < 0.001) than
those observed in benign ovarian tumor patients
(Table 2). We noticed also similarly significantly higher
concentrations of VEGF in I-IV (p = 0.044; p = 0.045;
p = 0.0001 and p = 0.044; respectively), of HE4 in I-IV
stages (p = 0.0184; p = 0.0014; p < 0.001 and p < 0.001),
and of CA125 in II-IV (p = 0.0341; p < 0.001 and
p < 0.001) stages of OC than in total benign lesion group.
The following observation of these two compared
groups revealed that the distribution of all tested factors
among two histological sub-types of cancer and among
non-carcinoma lesions patients (cystis) were significantly
different.
Additionally the median levels of CA125 in the two
histopathological sub-groups as well as in the total
group of benign lesions (cystis) were statistically higher
than in healthy subjects group (p < 0.001 in all cases).
VEGF obtained similar results but only in cystis serous
group (p = 0.0493). We have noticed also significant dif-
ferences in the concentrations of tumor markers (HE4;
CA125) when compared cystis endometrioidess (23.15
pmol/L; 43.75 U/ml; respectively) to cystis serous group
(43.25 pmol/L; 20.65 U/ml; respectively).
Table 2 Plasma levels of VEGF, HE4 and CA125 in tested groups
Groups VEGF HE4 CA125
(pg/ml) (pmol/L) (U/ml)
Ovarian cancer Median Range stage I 1/2 1/2 1
166.18 83.50 63.50
15.38 -656.56 28.60-1093.80 12.00-557.20
stage II 1/2 1/2 1/2
170.50 62.60 61.45
8.92-2701.07 27.00-625.10 9.80-998.00
stage III 1/2/4 1/2/4 1/2/4
345.50 117.90 766.60
10.70-1429.50 48.70-1500.00 10.10-2060.78
stage IV 1/2/4/5 1/2/4 1/2/4
143.50 198.00 531.90
9.00-1386.00 37.80-1944.20 14.30-8602.30
Total group 1/2 1/2 1/2
168.48 103.60 133.30
8.92-2701.07 27.00-1944.20 9.80-8602.30
Serous epithelial 1/6 1/6/7/9 1/6/7
166.18 126.00 171.21
8.92-1429.50 28.60-1944.20 9.80-8602.30
Endometrioid epithelial 1/6 1/6/7 1/6/7
184.24 68.45 114.00
9.00-2701.07 27.00-1740.00 11.10-1425.00
Control groups Median Range Benign ovarian tumor (Cystis) Endometrioides 3/8
45.50 23.15 43.75
9.00-560.50 14.00-65.60 7.50-2748.00






Healthy subjects 39.31 44.15 9.94
2.30-467.10 6.20-122.30 5.06-36.60
1statistically significant when comparing OC patients with healthy subject.
2statistically significant when comparing OC patients with benign ovarian tumor total group.
3statistically significant when comparing patients with benign ovarian tumor and healthy subject.
4 statistically significant when comparing OC patients in stage III or IV with stage I or stage II.
5 statistically significant when comparing OC patients in stage IV with stage III.
6 statistically significant when comparing with benign ovarian tumor group. i.e. type cystis endometrioides.
7statistically significant when comparing with benign ovarian tumor group. i.e. type cystis serous.
8 statistically significant when comparing patients with benign ovarian tumor. i.e. type cystis endometrioides with type cystis serous.
9 statistically significant when comparing OC patients. i.e. sub-type serous epithelial with sub-type endometrioid epithelial.
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tested: sensitivity (SE), specificity (SP), predictive value
of a positive (PV-PR) and negative (PV-NR) test result in
the OC patients. We observed higher ranges of the SE of
VEGF and tumor markers in more advanced ovarian
tumor stages (exception – HE4 in II stage and VEGF inIV stage). They were the highest for CA125. However,
VEGF and HE4 had better results in the group with
stage I and comparable results in the group with stage
III (with stage IV only for HE4) (Table 3). The combined
use of VEGF and tumor markers resulted in an increase
in the diagnostic SE to very high range in stage I: 76%
Table 3 The diagnostic criteria of VEGF tested and in combination analysis with HE4 and CA125 in ovarian cancer
patients
Epithelial ovarian cancer Diagnostic criteria (%) VEGF HE4 CA125 VEGF + HE4 VEGF + CA125 HE4+ CA125 VEGF + HE4 + CA125
I stage Sensitivity 44 44 40 76 72 72 84
Specificity 94 94 92 88 88 88 82
PV-PR 78 78 71 76 75 75 70
PV-NR 77 77 75 88 86 86 91
II stage Sensitivity 48 28 64 64 76 80 96
Specificity 94 94 92 88 88 88 82
PV-PR 75 70 80 72 76 76 72
PV-NR 74 72 83 83 88 89 97
III stage Sensitivity 72 68 80 88 92 88 96
Specificity 94 94 92 88 88 88 82
PV-PR 85 85 83 78 79 78 72
PV-NR 87 85 90 93 95 93 97
IV stage Sensitivity 40 80 84 88 92 92 96
Specificity 94 94 92 88 88 88 82
PV-PR 76 86 84 78 79 95 72
PV-NR 75 85 92 93 95 79 97
Total group Sensitivity 48 55 67 81 83 83 93
Specificity 94 94 92 88 88 88 82
PV-PR 94 94 94 93 93 93 91
PV-NR 47 51 58 69 72 72 85
Serous epithelial Sensitivity 46 70 64 81 77 88 94
Specificity 94 94 92 88 88 88 82
PV-PR 89 88 92 88 87 88 95
PV-NR 71 74 71 81 78 88 93
Endometrioid epithelial Sensitivity 50 36 69 71 91 80 95
Specificity 94 94 92 88 88 88 82
PV-PR 88 80 91 84 87 86 83
PV-NR 67 61 77 77 93 83 95
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markers (HE4, CA125), up to 84% (for VEGF +HE4 +
CA125). The maximum ranges (96%) were obtained for
the combinations of all parameters tested in stages II-IV
and in the total OC group (93%) (Table 3). We have no-
ticed also the highest ranges of diagnostic sensitivity
according to histological sub-type of OC: the serous epi-
thelial group for HE4 (70%), for the combination of HE4
and VEGF (81%) and of all parameters (94%) and in the
endometrioid epithelial group for CA125 (69%), for the
combination of CA125 and VEGF (91%), and of all pa-
rameters as well (95%).
The cytokine tested and tumor markers diagnostic
specificities (SP) presented high values: 94% - VEGF
and HE4; 92% - CA125. The combined use of studied
factors resulted in a decrease in the diagnostic SP
(Table 3).All parameters tested showed high predictive values of
a positive test result – PV-PR and a negative test result –
PV-NR in all the groups investigated. The PV-PR in the
total group of OC patients had very high and equal values
(94%) for all the parameters tested, the PV-NR was the
highest for CA125 (58%). The combined use of VEGF and
HE4 with CA125 for the remaining group resulted in a de-
crease in the PV-PR (91%) and in an increase in the PV-
NR (85%) values (Table 3). However, a maximum range of
PV-PR (as high as 95%) was obtained for the combination
of two tumor markers in stage IV and for the combination
of three parameters investigated in serous epithelial ovar-
ian cancer group. Similarly, a maximum range of PV-NR
(97%) was obtained also for the combination of all factors
in stages II, III and IV of ovarian cancer.
The Spearman’s rank correlation was used in the ana-
lyzes of dependence between the investigated parameters
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cant correlations in the OC group: negative between
HE4 and CA125 concentrations (R = −0.41; p = 0.036) in
II stage and positive between VEGF and HE4 (R = 0.28;
p < 0.001), VEGF and CA125 (R = 0.38; p < 0.001) and
also between HE4 and CA125 concentrations (R = 0.32;
p = 0.001) in the total group. Statistically significant
positive correlations were also observed between
the HE4 and CA125 levels in the serous epithelial
(R = 0.35; p = 0.008) and endometrioid epithelial
(R = 0.31; p = 0.037) ovarian cancer patients. Further-
more, a significant positive correlations were noticed be-
tween the VEGF and CA125 concentrations in the
benign ovarian lesions group: cystis serous as well as in
total group (R = 0.39; p = 0.012 and R = 0.23; p = 0.040;
respectively). Similarly, significant positive correlation
between the VEGF and HE4 levels in the healthy control
group (R = 0.35; p = 0.012) was showed.
The relationship between the diagnostic SE and SP
was illustrated by the ROC (receiver-operating charac-
teristics) curve. Table 4 shows the results of our in-
depth analysis of the AUC (area under ROC curve) of
every parameter alone and in combination for every
stage and for every investigated histological sub-type of
the disease. It shows that the CA125 area (0.9276) under
the ROC curve is the largest in the total group and both
in the groups with serous epithelial (0.9047) and
endometrioid epithelial (0.9128) sub-type (Table 4). The
AUC of CA125 is the largest also in the group of pa-
tients with stage II (0.8652) and IV (0.9472), but inter-
estingly the AUC of VEGF is the largest in the group
with stage I (0.7984) and of HE4 with stage III tumor
(0.9256). In addition, the AUC of cytokine tested and
HE-4 presented distinctly the increase with stage of ad-
vancement of OC (with exception of VEGF in IV stage),
identically as CA125. The combination of all parameters
resulted in a further increase in the area under the ROC
curve in every case, to the value: 0.8990 in I stage;
0.9207 in II stage; 0.9600 in IV stage, 0.9404 in total
group, the maximum value was obtained in III stage
(0.9837). Similarly, the areas under the ROC curve were
also the largest for the combination of three parameters
in each cancer sub-type group (0.9395; 0.9414). More-
over, the AUCs of the VEGF or commonly accepted
tumor markers were significantly higher compared to
AUC = 0.5 in every group studied of OC (Table 4).
Discussion
Establishment of an appropriate screening test for ovar-
ian cancer has long been sought. Symptoms that are as-
sociated with this malignancy are typically nonspecific
and the association is often not recognized until the dis-
ease is advanced [32]. Elevated serum CA125 levels have
been detected in 50% and 92% of OC in early and latestages, respectively [33], similarly to the results observed
for HE4 [34]. Several studies have aimed to explore the
link between serum VEGF levels and ovarian cancer
[27,28].
In this study, we investigated the diagnostics useful-
ness of VEGF and in combination with HE4 and CA125
in the patients with epithelial ovarian malignancies. Ana-
lysis of the usefulness of cytokine alone or in combin-
ation with other tumor markers, may improve the
effectiveness of non-invasive diagnostics of this cancer
[35]. Furthermore, we made a comparison of the re-
ceived results with the results of the tumor markers and
with the control groups (benign ovarian lesions patients
and healthy subjects). Additionally, we estimated the
diagnostic utility of mentioned above parameters in cor-
relation to the stage of ovarian cancer.
Our results show that VEGF concentrations as well as
HE4 and CA125 levels in all groups of ovarian cancer
patients were statistically significantly higher in compari-
son to the group of healthy subjects and patients with
benign tumors (exception CA125 I stage). These data
are very similar to the studies of other authors, who
compared patients with ovarian [36-40] or breast cancer
[41] with healthy volunteers however, there were differ-
ences in the number of patients. Our results are consist-
ent with the results of Sedlakova et al. [40] and Li et al.
[39] who observed increased levels of VEGF in the group
of ovarian cancer patients compared to the benign ovar-
ian tumor patients, although the tested groups with
non-malignant lesions were much smaller (15 and 25
women respectively). Similar results were also received
by Cheng and others [42] who observed higher concen-
trations but of VEGF-C in ovarian cancer (109 patients)
in comparison to different benign gynecological lesions
(76 subjects). In opposition to our observations there
was no difference in the VEGF concentrations between
OC patients and benign tumors group although only 7
serous malignant and 3 borderline tumors were included
[43]. Significantly higher serum levels of CA125 and
HE4: (p = 0.005) [44] or (p < 0.0001) [38,45] were found
in OC patients than in those with benign diseases
though there was various composition and menopausal
status of the groups compared.
Moreover, it was observed that VEGF concentrations,
similarly to HE4 and CA125, were statistically higher in
every group (the analysis related to the stage of advance-
ment of ovarian cancer), compared to the healthy con-
trols. Similar results were confirmed by different authors
[42], though they observed the highest concentrations of
VEGF-C in more advanced stages and various sub-types
of OC were enrolled in the study (serous-papillary, mu-
cinous, endometrioid, clear cell). Interestingly, it was
found that VEGF concentrations in serum significantly
surpassed the control level in breast cancer patients














I stage AUC 0.7984* 0.7284* 0.7652* 0.8632* 0.8784* 0.8327* 0.8980*







0.764-0.963 0.785-0.971 0.727-0.938 0.813-0.83
p AUC = 0.5 <0.001 0.0013 0.0005 <0.001 <0.001 <0.001 <0.001
II stage AUC 0.7231* 0.7646* 0.8652* 0.8592* 0.8587* 0.9207* 0.9207*







0.777-0.942 0.759-0.959 0.859-0.982 0.863-0.978
p AUC = 0.5 0.0006 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
III stage AUC 0.9012* 0.9256* 0.9112* 0.9680* 0.9665* 0.9763* 0.9837*







0.935-1.001 0.923-1.010 0.902-1.020 0.960-1.007
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
IV stage AUC 0.7168* 0.9124* 0.9472* 0.9240* 0.9494* 0.9420* 0.9600*







0.849-0.999 0.888-1.011 0.873-1.011 0.905-1.015
p AUC = 0.5 0.0027 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Total group AUC 0.7843* 0.8321* 0.9276* 0.9032* 0.9127* 0.9180* 0.9404*







0.856-0.950 0.864-0.962 0.874-0.962 0.904-0.977
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Serous epithelial AUC 0.7522* 0.8720* 0.9047* 0.9124* 0.9009* 0.9391* 0.9395*







0.858-0.967 0.840-0.962 0.893-0.985 0.894-0.985
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Endome-trioid epithelial AUC 0.8226* 0.7843* 0.9128* 0.8922* 0.9268* 0.8926* 0.9414*







0.829-0.955 0.868-0.985 0.828-0.957 0.897-0.986
p AUC = 0.5 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
C.I. confidence intervals of AUC.
* statistically significant when comparing tested parameters AUC’s with 0.5 AUC’s.
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tions of HE4 and CA125 significantly higher in patients
with stage IA-IIB compared with healthy women, though
more than four sub-types of ovarian cancer were in-
cluded in the investigation and there was different the
ethnical characteristics of the population selected [36].
Furthermore, significantly elevated levels of all param-
eters tested in the groups with early and late stage of
ovarian cancer were observed compared to the cyst
group. Our results are in agreement with differentpublications about our studied comparative tumor
markers [36,46,47]. We were unable to confirm findings
about VEGF in the papers published, since no reports
on the subject are available.
The analysis of research results from literature revealed
also almost identical to our observations significant differ-
ences when comparing patients in more advanced stage to
metastasis-free early stage [36,39,40,46], and is in opposition
to another publication where a half smaller group of post-
menopausal women was studied [48]. It should be
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significant difference in the concentrations between the two
groups with more advanced stage of OC (III and IV –
higher values for III stage). This may indicate the highest
diagnostic usefulness of VEGF in locally advanced and me-
tastases free stages of OC. One possible explanation for rela-
tively low levels in patients with IV stage could be that
VEGF is rapidly metabolized and excreted in case of
presence many small, metastatic tumors. To our knowledge,
little is known about the pharmacokinetic or pharmacody-
namic characteristics of this cytokine. Undoubtedly, VEGF
plays an essential role in the growth and metastases of ovar-
ian cancer. Mattern and colleagues [49] showed the close
correlation of VEFG expression with tumor cell prolifera-
tion. Vascular endothelial growth factor may also contribute
to ovarian cancer metastasis by directly stimulating prolifer-
ation, survival, and/or migration of tumor cells [50]. It has
been validated by others that serum VEGF was an inde-
pendent prognostic parameter in a large series of patients
with all stages of OC [27].
To date no large studies had examined VEGF levels in
healthy postmenopausal women with benign gynecological
disorders. Cheng and colleagues [42] found no differences
between benign ovarian diseases and healthy controls for
serum levels of VEGF-C and CA125 (p > 0.05), though pa-
tients with cystis serous or cystis endometrioides were not en-
rolled in the group studied.
In opposition, we found in our previous study signifi-
cant higher concentrations of CA125 in the group of 70
postmenopausal women with benign lesions of the ovary
(cysts) [51]. Our present observations about both tumor
markers are in agreement with published evidence [47].
We showed the VEGF concentrations significantly dif-
ferent in the patients with studied sub-types of OC vs
patients with cystis endometrioides, though we did not
observe statistical differences in the concentrations of
mentioned above cytokine between the two control
groups: patients with cystis endometrioides and the
healthy women group. On the basis of obtained results
the VEGF could be presented as a useful diagnostic tool
for the differentiation of patients with OC sub-type
endometrioid epithelial, though we can not confirm
these findings by other publications. Similarly to the
discussed above results, HE4 also presented usefulness
in the diagnostics of both investigated sub-types of OC.
Moreover, patients with serous epithelial OC had signifi-
cantly higher plasma levels of HE4 than patients with
endometrioid epithelial OC. Patients with benign
endometrioid epithelial ovarian tumors had lower HE4
and higher CA125 concentrations than patients with be-
nign serous epithelial ovarian tumors. These data are in
variance with previous observations [44,52], and may be
in part affected by the patients’ selection, though other
studies have recently reported similar results [46]. Inagreement with the publications of Li et al. [39] and
Czekierdowski et al. [48] we found no significant differ-
ences in VEGF levels among different pathological sub-
types of ovarian carcinoma.
The correlation between examined markers levels was es-
timated by Spearman’s rank correlation test, because the
value of each marker was not in a parametric distribution.
Most of the measured values tended to be increased for
every marker and in opposition to the publications of Tan
and colleagues [53] we found a positive correlation between
preoperative VEGF and CA125 levels, similarly to the other
publication (r = 0.44; p = 0.0015) [43], though Manher et al.
[54] found these parameters inversely correlated (r = −0.460;
p = 0.01). Furthermore, we found positive correlation be-
tween these two mentioned above parameters also in con-
trol group (cysts) in opposition to the results of others
(r = 0.10; p = 0.28) [43] and between VEGF and HE4 in
healthy individuals group but no publications could confirm
our findings. In accordance to demonstrated in our study re-
sults some authors showed positive correlation between
CA125 and HE4 levels among patients with ovarian carcin-
oma (r = 0.54 p < 0.0001) [37,55].
The ability to detect early cancers would definitely im-
prove patient prognosis. It was demonstrated that the
diagnostic sensitivity increased with the progress of can-
cer disease and was the highest for CA125 (from 40% in
stage I up to 84% in stage IV of the disease). Our results
are in agreement with the literature [33]. On the other
side, we could not demonstrate a better sensitivity than
CA125 for ovarian cancer by alone VEGF testing, neither
in early stages nor in advanced stages (though SE of this
cytokine reached equal or even higher values to HE4 in
particular stages). This could be explained by other au-
thors’ investigations that levels of detectable VEGF in
serum may depend on the binding to vascular endothe-
lium or soluble receptors and/or degradation. In
addition, VEGF levels in serum may also depend on the
biosynthesis and release of VEGF from blood mono-
nuclear cells and activated platelets [56]. It is interesting
to point out that we found out a maximum increase in
the diagnostic sensitivity for the combination of all pa-
rameters tested to 84% in stage I, even to 96% in stages
II-IV, and to 94-95% in every histological sub-type of
OC. Results of this study suggest that combining VEGF
with CA125 and HE4 measurements might enable im-
proved early detection of this cancer as compared with
use of either marker alone or of both comparative tumor
markers. This observation is in accordance to our previ-
ous papers, in which we evaluated diagnostic criteria of
selected cytokines and commonly used tumor markers
in various gynecological malignancies [51,57,58]. Several
studies have found sensitivity to be greater than in either
marker alone: VEGF and CEA (carcinoembrionic anti-
gen) in colorectal [59] or HE4 and CA125 in ovarian
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very high and reached the value of 94% for VEGF and
HE4, and 92% for CA125. We found similar results in
the existing literature [37,39,44].
The positive predictive value of the parameters tested
were high in the total group of OC (94%). The negative
predictive value shows the ability to exclude malignant
disease and was the highest for CA125 (58%) in the total
group of OC, though in current study the combination
of both comparative tumor markers or with VEGF had
unquestionable higher value (95%). These observations
are in agreement with those recently reported by Molina
et al. [44] and in opposition to the results of other au-
thors who observed higher values of PV-NR for CA 125
or HE4 alone (92% and 72%; respectively) in Asian
women [60], or distinctly higher values of these diagnos-
tic criteria for HE4 than CA125 though for comparison
of epithelial OC vs various benign lesions of the ovary in
premenopausal women [61]. We were unable to com-
pare our findings about VEGF by the papers published,
since no reports on the subject are available. The results
of the current study support our previous findings regarding
another cytokine - M-CSF in this malignancy [51].
The area under the ROC curve (AUC) indicates the
clinical usefulness of a tumor marker. Our results show
that CA125 had the highest diagnostic power from the
parameters tested in the total group of OC patients
(AUC = 0.9276) and its value was negligibly higher than
that of HE4 (AUC = 0.8321). Interestingly, VEGF had the
largest AUC (0.7984) in the patients with I stage, and
comparable to HE4 in patients with II and III stage.
Diagnostic accuracy was increased when three parame-
ters were included resulting in the highest diagnostic
power in every group studied regarding to the stage and
histological sub-type of epithelial OC. Furthermore, we
observed that the areas under the curve for VEGF and
comparative markers were statistically significantly larger
compared to AUC = 0,5 - borderline of diagnostic useful-
ness of the test. Test data published by Candido dos Reis
and colleagues [43] indicated area under the ROC curve
– 0.99 for VEGF in diagnosis of epithelial ovarian tu-
mors, though the cyst fluid was used as a material for
the assay. In contrary to the current results Cheng et al.
[42] found the AUC of VEGF-C larger than CA125 in
different screening groups: OC versus benign ovarian
diseases and healthy controls (0.826; 0.760; respectively),
OC vs healthy individuals (0.862; 0.853) and finally OC
vs benign ovarian diseases (0.802; 0.681). In a few previ-
ous studies the AUC values of CA125 and HE4 for dif-
ferentiating ovarian cancer were 0.82-0.95 and 0.85-0.96,
respectively [37,38,45-47,62] and was significantly higher
for the combination of mentioned above markers [62]
which were similar to our findings. Slight differences of
the results between the studies might be caused bydifferences in the number of patients and the histo-
logical types or disease stages of ovarian cancer enrolled
in each study.
Conclusions
In summary, to the authors’ knowledge, the diagnostic
usefulness of VEGF independently and especially in
combination with both established ovarian tumor
markers has not been previously described in the litera-
ture. Results of this study suggest that combining VEGF,
HE4 and CA125 measurements might enable improved
early detection of OC as compared with use of either
marker alone. Additionally, VEGF is the most useful tool
in the diagnostics of locally advanced ovarian cancer
without metastases. Investigated cytokine presented
similar to HE4 usefulness in differentiation of OC
according to its histopathlogical sub-type, and could be
used especially in the diagnostics of endometrioid epithe-
lial OC.
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